首頁 > 市場調查報告書 > 製藥

婦科治療

市場調查報告書

商品編碼

1482456

全球性交困難治療市場：依藥物類型、給藥途徑、通路及地區分類

Dyspareunia Treatment Market, By Drug Type (Selective Estrogen Receptor Modulators, Estrogens, Corticosteroids, Antibiotics, and Others), By Route of Administration, By Distribution Channel, By Geography

出版日期: 2024年04月10日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球性交困難治療市場規模將達7.541億美元，2024年至2031年年複合成長率為4.6%，2031年將達到10.354億美元。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	7.541 億美元
實際資料	2019-2023	預測期	2024-2031
預測期，2024-2031年年複合成長率：	4.60%	2031年金額預測	10.354 億美元

圖：2024年依地區分類的性交困難治療市場佔有率（%）

性交困難（性交疼痛）是全世界女性常見的問題。其特徵是插入期間或插入後骨盆區域內或周圍疼痛，並對身體和心理產生影響。確切原因因人而異，但常見原因包括陰道感染疾病、子宮內膜異位症、心理因素、分娩時骨盆區域受傷。如果不及時治療，可能會對生活品質和性關係產生負面影響。性功能障礙治療市場包括一系列緩解疼痛和恢復親密關係的藥物和醫療設備。荷爾蒙療法、物理治療和微創手術等治療領域的進步擴大了有效治療這種疾病的選擇。

市場動態：

人們對現有治療方案的認知不斷提高，對女性性行為的討論也更加公開，推動性交困難治療市場的發展。隨著患者感覺更有權力尋求治療，圍繞女性健康問題的歷史恥辱逐漸減少。對藥理管理的非侵入性和非藥物替代品的需求不斷成長，日益擴大該領域物理治療工具和醫療設備的機會。然而，新技術的高成本可能會在一定程度上限制市場擴張。文化和社會障礙繼續阻礙一些地區的尋求幫助。同時，患有骨盆底疾病和神經系統問題的人口老化為市場參與企業帶來了新的前景。

本研究的主要特點

本報告詳細分析了全球性交困難治療市場，包括以2023年為基準年的預測期（2024-2031年）的市場規模（百萬美元）和年複合成長率（CAGR%）。
強調了各個細分市場的潛在收益成長機會，並說明了該市場有吸引力的投資提案矩陣。
提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球性功能障礙治療市場的主要企業。
本報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球性交困難治療市場迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球性交困難治療市場的各種策略矩陣來促進他們的決策。

公司簡介
- Lupin
- Pfizer Inc.
- AbbVie Inc.
- Duchesnay Inc.
- AMAG Pharmaceuticals, Inc.
- Amneal Pharmaceuticals LLC.
- TherapeuticsMD, Inc.
- Sumitomo Pharma Co., Ltd.,
- Myovant Sciences
- Novo Nordisk A/S
- Viatris Inc.
- Shionogi & Co., Ltd.
- Millicent Pharma Ltd.
- Cosette Pharmaceuticals, Inc.
- Mundipharma International

第10章分析師的觀點

第11章參考文獻與調查方法

簡介目錄

Product Code: CMI6885

The dyspareunia treatment market is estimated to be valued at USD 754.1 Mn in 2024 and is expected to reach USD 1,035.4 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 754.1 Mn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	4.60%	2031 Value Projection:	US$ 1,035.4 Mn

Figure. Dyspareunia Treatment Market Share (%), By Region 2024

Dyspareunia, or painful sexual intercourse, is a prevalent issue that affects women globally. It is characterized by pain in the pelvic region or surrounding area during or after penetration, and has physical as well as psychological implications. The exact causes may vary from person to person, but common contributors include vaginal infections, endometriosis, psychological factors, and pelvic area injuries during childbirth. If left untreated, it can have a negative impact on quality of life and sexual relationships. The dyspareunia treatment market consists of pharmaceutical and medical device options that provide relief from pain and help restore intimacy. Advancements in therapeutic areas like hormonal therapy, physical therapy, and minimally invasive procedures are expanding choices for managing this condition effectively.

Market Dynamics:

Rising awareness about available treatment choices and more open discussion of female sexuality are driving the dyspareunia treatment market. Historical stigma around women's health issues is gradually reducing as patients feel more empowered to seek care. Growing demand for non-invasive and non-drug alternatives to pharmacological management is opening up opportunities for physical therapy tools and medical devices in this space. However, high costs associated with newer technologies could restrict market expansion to some degree. Cultural and social barriers continue to hamper help-seeking behavior in certain regions as well. Meanwhile, an aging population presenting with pelvic floor disorders and neurological issues presents new prospects for market participants.

Key Features of the Study:

This report provides an in-depth analysis of the global dyspareunia treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dyspareunia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes Lupin, Pfizer Inc., AbbVie Inc., Duchesnay Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., TherapeuticsMD, Inc., Sumitomo Pharma Co., Ltd., Myovant Sciences, Novo Nordisk A/S, Viatris Inc., Shionogi & Co., Ltd., Millicent Pharma Ltd., Cosette Pharmaceuticals, Inc., and Mundipharma International
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dyspareunia treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dyspareunia treatment market

Detailed Segmentation-

Drug Type:
- Selective Estrogen Receptor Modulators
- Estrogens (Miscellaneous Vaginal Agents)
- Corticosteroids
- Antibiotics
- Others
Route of Administration:
- Oral
- Vaginal Inserts
- Others
Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- E-Commerce
- Others
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Lupin
- Pfizer Inc.
- AbbVie Inc.
- Duchesnay Inc.
- AMAG Pharmaceuticals, Inc.
- Amneal Pharmaceuticals LLC.
- TherapeuticsMD, Inc.
- Sumitomo Pharma Co., Ltd.,
- Myovant Sciences
- Novo Nordisk A/S
- Viatris Inc.
- Shionogi & Co., Ltd.
- Millicent Pharma Ltd.
- Cosette Pharmaceuticals, Inc.
- Mundipharma International

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Product Launches/Approvals
Fundings and Investments
Reimbursement Scenario
PEST Analysis
Porter's Analysis

4. Global Dyspareunia Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Dyspareunia Treatment Market, By Drug Type, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Selective Estrogen Receptor Modulators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Estrogens (Miscellaneous Vaginal Agents)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Dyspareunia Treatment Market, By Route of Administration, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Vaginal Inserts
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Dyspareunia Treatment Market, By Distribution Channel, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
E-commerce
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Dyspareunia Treatment Market, By Region, 2019 - 2031, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - U.S.
  - Canada
  - Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
  - Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
  - Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
  - Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Lupin*
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Duchesnay Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AMAG Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amneal Pharmaceuticals LLC.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- TherapeuticsMD, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sumitomo Pharma Co., Ltd.,
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Myovant Sciences
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novo Nordisk A/S
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Viatris Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Shionogi & Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Millicent Pharma Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Cosette Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Mundipharma International
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies